Telix Pharmaceuticals Limited American Depositary Shares (TLX) Financials
Key financial figures for Telix Pharmaceuticals Limited American Depositary Shares (Q2 2026).
Telix Pharmaceuticals Limited reported revenue of $476.0 million for Q2 FY2026, up 151.9% from the same period a year earlier. Net income was $38.2 million, or $0.11 per share. Operating margin came to -2.88%, against 7.28% a year earlier. Free cash flow for the period was $4.1 million. Across the last 5 reported quarters, quarterly revenue has risen from $189.0 million in Q2 FY2024 to $476.0 million in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Telix Pharmaceuticals Limited are on the SentiSense financials page.
- Revenue
- $476M
- Net Income
- $38M
- EPS
- $0.11
- Total Assets
- $1.4B
- Operating Cash Flow
- $23M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $476M | $38M | $0.11 | -2.88% | $4M |
| Q4 FY2025 | $410M | -$5M | -$0.01 | 1.58% | -$61M |
| Q2 FY2025 | $355M | -$2M | -$0.01 | 2.66% | $10M |
| Q4 FY2024 | $594M | $38M | $0.11 | 11.51% | -$6M |
| Q2 FY2024 | $189M | $29M | $0.03 | 7.28% | $30M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $790M | -$7M | -$0.02 | 2.21% | -$54M |
| FY2024 | $783M | $50M | $0.14 | 10.49% | $29M |
| FY2023 | $503M | $5M | $0.02 | 3.15% | $14M |
Frequently asked questions
What was Telix Pharmaceuticals Limited's revenue last quarter?
Telix Pharmaceuticals Limited reported revenue of $476.0 million for Q2 FY2026, up 151.9% from the same period a year earlier.
Is Telix Pharmaceuticals Limited profitable?
Yes. Telix Pharmaceuticals Limited reported net income of $38.2 million for Q2 FY2026, a net margin of 8.03% on revenue.
How has Telix Pharmaceuticals Limited's margin trended?
Operating margin was -2.88% in Q2 FY2026, compared with 7.28% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Telix Pharmaceuticals Limited generate?
Telix Pharmaceuticals Limited generated free cash flow of $4.1 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Telix Pharmaceuticals Limited American Depositary Shares on SentiSense, with up to forty quarters and twenty fiscal years of history.